A phase I clinical study showed that the combination of galinpepimut-S with nivolumab showed a tolerable toxicity profile and induced immune phenotypic changes and WT1-specific IgG production in patients with WT1-expressing ovarian cancer, with a 1-year PFS of 70% [86]. This evidence concerns the gene WT1 and ovarian carcinoma.